Australia’s Health Technology Assessment system uses comparative evaluation to determine the value of medicines against a relevant comparator. Comparator selection has increasingly defaulted to the lowest cost comparator. This analysis finds that the lowest cost comparator use has become systemic, creating structural barriers to patient access. It provides a phased roadmap proposing eight actions.

Chronic obstructive pulmonary disease (COPD) is one of Australia’s most common yet most overlooked chronic diseases. This report highlights how better management of COPD can reduce preventable hospitalisations, lower mortality and curb the growing economic and societal burden. It outlines five key recommendations that could chart a new course for COPD care to deliver measurable...

Antimicrobial resistance is a critical global health challenge, threatening the effectiveness of modern medicine and increasing the risk of untreatable infections. This report summarises discussion at the 2024 Antimicrobial Subscription Model roundtable. The roundtable agreed on 10 key principles to guide the development of a pilot program for novel antimicrobials and its implementation in Australia.

Despite the severity of motor neurone disease (MND), people with MND face a fragmented and inequitable system of care. A major driver of inequity is an age-based divide in funding. This report aims to guide policy decisions that enhance care, support and quality of life for people living with this condition and their carers.

Hypophosphatasia (HPP) is a genetic, multisystem condition that impairs the body’s ability to properly mineralise bones and teeth. Through the lens of HPP, this report illustrates how Australia’s healthcare system remains unfit for people with rare diseases. It presents a clear case for targeted, achievable reforms to improve diagnosis, treatment access and care coordination for...